[go: up one dir, main page]

MX2009010727A - Heterociclos como antagonistas de orexina. - Google Patents

Heterociclos como antagonistas de orexina.

Info

Publication number
MX2009010727A
MX2009010727A MX2009010727A MX2009010727A MX2009010727A MX 2009010727 A MX2009010727 A MX 2009010727A MX 2009010727 A MX2009010727 A MX 2009010727A MX 2009010727 A MX2009010727 A MX 2009010727A MX 2009010727 A MX2009010727 A MX 2009010727A
Authority
MX
Mexico
Prior art keywords
halogen
lower alkyl
lower alkoxy
substituted
compounds
Prior art date
Application number
MX2009010727A
Other languages
English (en)
Inventor
Mark Rogers-Evans
Emmanuel Pinard
Olivier Roche
Henner Knust
Parichehr Malherbe
Matthias Nettekoven
Luca Gobbi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39469467&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009010727(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009010727A publication Critical patent/MX2009010727A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (ver fórmula (I)) en la que R1/R2 son con independencia entre sí hidrógeno o alquilo inferior; R3 con independencia del número de sustituyentes es hidrógeno, halógeno, alquilo inferior, alquilo inferior sustituido por halógeno, alcoxi inferior o alcoxi inferior sustituido por halógeno; R4 es halógeno, alquilo inferior, alquilo inferior sustituido por halógeno, alcoxi inferior o alcoxi inferior sustituido por halógeno; Hetarilo es un anillo heteroaromático que tiene uno o dos ciclos, está conectado a los átomos de carbono del resto piperidina y se elige entre el grupo formado por (ver fórmula) o a las sales de adición de ácido farmacéuticamente idóneas, los enantiómeros ópticamente puros, los racematos o mezclas diastereoméricas del mismo. Se ha encontrado que los compuestos de la fórmula I son antagonistas de receptor de orexina y los compuestos en cuestión pueden ser útiles para el tratamiento de trastornos, en los que intervienen los mecanismos de la orexina, por ejemplo los trastornos del sueño.
MX2009010727A 2007-04-04 2008-03-26 Heterociclos como antagonistas de orexina. MX2009010727A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07105596 2007-04-04
PCT/EP2008/053545 WO2008122513A1 (en) 2007-04-04 2008-03-26 Heterocycles as orexin antagonists

Publications (1)

Publication Number Publication Date
MX2009010727A true MX2009010727A (es) 2009-10-26

Family

ID=39469467

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010727A MX2009010727A (es) 2007-04-04 2008-03-26 Heterociclos como antagonistas de orexina.

Country Status (16)

Country Link
US (1) US8067598B2 (es)
EP (1) EP2144906B1 (es)
JP (1) JP2010523518A (es)
KR (1) KR101158976B1 (es)
CN (1) CN101646668A (es)
AR (1) AR065904A1 (es)
AT (1) ATE512963T1 (es)
AU (1) AU2008235528B2 (es)
CA (1) CA2681163A1 (es)
CL (1) CL2008000957A1 (es)
ES (1) ES2365444T3 (es)
IL (1) IL200781A0 (es)
MX (1) MX2009010727A (es)
PE (1) PE20081900A1 (es)
TW (1) TW200845973A (es)
WO (1) WO2008122513A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2451281A4 (en) * 2009-07-09 2013-03-13 Merck Sharp & Dohme TETRAHYDRONAPHTHYDRIN-orexin receptor Antagonist
US20120258957A1 (en) 2009-11-23 2012-10-11 Matilda Jane Bingham Heterocyclic derivatives
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
HK1204955A1 (zh) 2012-02-07 2015-12-11 Eolas Therapeutics Inc. 取代的脯氨酸/哌啶用作食慾素受體拮抗劑
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
SMT202200323T1 (it) 2016-02-12 2022-09-14 Astrazeneca Ab Piperidine alo-sostituite come modulatori del recettore di oressina

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE286500T1 (de) * 2000-03-14 2005-01-15 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisochinolin-derivate
WO2002051232A2 (en) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
JP3876872B2 (ja) * 2002-10-15 2007-02-07 ソニーケミカル＆インフォメーションデバイス株式会社 エレクトロルミネスセンスポリマー、ビスフルオレニルシラン化合物及び有機ｅｌ素子
BRPI0408681A (pt) 2003-03-26 2006-03-28 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
RU2378257C2 (ru) * 2004-03-01 2010-01-10 Актелион Фармасьютиклз Лтд Замещенные производные 1,2,3,4-тетрагидроизохинолина
UA93903C2 (ru) * 2006-03-15 2011-03-25 Актелион Фармасьютикалз Лтд Производные тетрагидроизохинолина для повышения функции памяти
DE602007012072D1 (de) * 2006-04-26 2011-03-03 Actelion Pharmaceuticals Ltd Orantagonisten

Also Published As

Publication number Publication date
KR20090127313A (ko) 2009-12-10
ATE512963T1 (de) 2011-07-15
EP2144906B1 (en) 2011-06-15
CL2008000957A1 (es) 2008-10-10
PE20081900A1 (es) 2009-01-26
AU2008235528A1 (en) 2008-10-16
AR065904A1 (es) 2009-07-08
CN101646668A (zh) 2010-02-10
TW200845973A (en) 2008-12-01
ES2365444T3 (es) 2011-10-05
WO2008122513A1 (en) 2008-10-16
IL200781A0 (en) 2010-05-17
US20080249125A1 (en) 2008-10-09
KR101158976B1 (ko) 2012-06-21
US8067598B2 (en) 2011-11-29
AU2008235528B2 (en) 2012-11-08
CA2681163A1 (en) 2008-10-16
JP2010523518A (ja) 2010-07-15
EP2144906A1 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
MX2009010727A (es) Heterociclos como antagonistas de orexina.
MX2009009384A (es) Malonamidas como antagonistas de orexina.
MX2010001486A (es) Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
MX2009009121A (es) Aminoamidas como antagonistas de orexina.
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
WO2009065919A3 (de) Organische verbindungen
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
WO2009065920A3 (de) Verbindungen
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
UA99361C2 (uk) ТРИАЗИНИ ЯК ІНГІБІТОРИ PІ3-КІНАЗИ І mTOR
TNSN07272A1 (en) Substituted bis aryl and heteroaryl compounds as selective 5ht 2a antagonists
WO2010018109A3 (en) Substituted aminotetralines
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
ME02200B (me) Postupci za korisćenje alk inhibitora
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
WO2009065922A3 (de) Organische verbindungen
MX2010001774A (es) Pirrolidin aril-eteres como antagonistas de receptores de nk3.
MX2009013885A (es) Derivados de quinolina fusionados utiles como moduladores de acido gamma-aminobutirico.
UA96947C2 (ru) Производные циннамоил-пиперазина и их применение как антагонистов par-1
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
MX2010003849A (es) Antagonistas de cgrp.
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration